Vinpocetine
Best-in-class: Vinpocetine
A compound that increases cerebral blood flow and glucose/oxygen use in the brain — used for memory, focus and cognitive circulation.
Vinpocetine quick facts
| Suggested dose | 10–30 mg daily with food. |
| How often | daily |
| Who it's for | Memory and cerebral-circulation support. |
Used clinically in Eastern Europe for cerebrovascular insufficiency with a reasonable trial base. The important caution is regulatory and reproductive: several agencies have warned against use in pregnancy or by women who could become pregnant, following evidence of reduced fetal weight and possible miscarriage risk. It also has antiplatelet activity. Not a casual nootropic.
How Vinpocetine actually works
A semi-synthetic derivative of vincamine from periwinkle. It blocks voltage-gated sodium channels and inhibits phosphodiesterase-1, producing selective cerebral vasodilation — selective meaning it increases flow to ischemic regions without stealing from healthy ones, which is the opposite of what many vasodilators do. It also improves erythrocyte deformability, so red cells pass through capillaries more easily.
Where to get Vinpocetine
Find Vinpocetine on iHerb →The evidence for Vinpocetine
Graded by what exists behind each claim.
✅ Clinically validated
- Studies show improved cerebral blood flow and memory/cognition, especially in vascular cognitive issues.
- Enhances brain metabolism and has neuroprotective effects.
📊 Correlative data
- No meaningful observational or traditional-use literature — a synthesized or isolated compound whose entire evidence base is trials and mechanism. Worth stating rather than leaving blank: it means there is no population-level signal either supporting or contradicting what the trials show.
🧪 Theoretical / extrapolated benefits
- Best evidence is in older/vascular populations; healthy-user benefits are subtler.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Vinpocetine actually does
Vinpocetine is not a periwinkle extract. It is the ethyl ester of apovincaminic acid, made in a factory from vincamine, and it has been a prescription medicine in Hungary and much of eastern Europe for decades, under the name Cavinton Dong 2024. Everything below follows from that: this is a small synthetic molecule with drug pharmacology, sold in the United States next to the fish oil.
Target one: phosphodiesterase 1. PDE1 is the calcium/calmodulin-activated phosphodiesterase, and that activation clause is the whole interest of it. PDE1 only degrades cyclic nucleotides briskly where intracellular calcium is already rising, so inhibiting PDE1 raises cAMP and cGMP selectively in cells that are being stimulated rather than everywhere at once. In vascular smooth muscle that means cGMP-driven relaxation and a vasodilator effect on cerebral vessels; in neurons it means cyclic-nucleotide signaling is sustained through exactly the calcium transients that carry synaptic plasticity Shekarian 2023.
Target two, and it is the one that is almost never printed: voltage-gated sodium channels. Vinpocetine blocks them, in the use-dependent way an antiepileptic does — more block where channels are firing fastest. That is not a footnote, it is the more plausible explanation of the ischemia results. Less sodium entry means less reversal of the sodium-calcium exchanger, less calcium overload and less glutamate dumped into the synapse, which is the classic excitotoxic cascade Dong 2024. A cerebral vasodilator and a sodium channel blocker are two very different drugs, and only one of them has anything to do with the “brain blood flow” story on the bottle.
What you actually circulate is not vinpocetine. The ester is hydrolyzed and heavily extracted on first pass; the species that persists in plasma is the acid metabolite, apovincaminic acid, and the only published population pharmacokinetic model for this compound is a model of the metabolite rather than of the parent Petric 2023. Any dose-response reasoning about vinpocetine that does not mention apovincaminic acid is reasoning about a molecule that is mostly gone.
Cell, rodent, human — and where it stops
In cultured embryos. Rat whole-embryo culture, vinpocetine and apovincaminic acid tested separately: both produced concentration-dependent bradycardia, with the lowest effective vinpocetine concentration at 100 nM, and frank embryonic arrhythmias at the highest concentrations Ritchie 2023. Note which endpoint that is. The first cell-level result in this entry is a toxicology result, not an efficacy one.
In rodents. Sixty adult male Wistar rats, vinpocetine 4 mg/kg by gavage given before, after or both around an intracerebroventricular injection of beta-amyloid. Vinpocetine prevented the amyloid-induced impairment of hippocampal long-term potentiation Shekarian 2023. Real electrophysiology, real dose, real route — and an animal into whose ventricles a peptide has been injected.
In people. The pooled human evidence is a meta-analysis of 4 randomized trials, 601 patients on vinpocetine against 236 on placebo, in acute ischemic stroke. It reported reduced death or disability at 1 to 3 months with relative risks of 0.80 and 0.67, lower disability scores with standardized mean differences of 0.49 to 1.22, and better cognitive scores Panda 2022.
The obstacle, stated in one sentence: that is a hospital population, enrolled within days of a stroke, treated in a ward, and the reader is a well person swallowing 10 to 30 mg with breakfast hoping to concentrate better. There is no randomized trial of vinpocetine for attention, working memory or fatigue in healthy adults at any dose or duration. The gap between the evidence and the use is not a matter of degree here; the endpoint itself has never been measured in this population.
Vinpocetine — which form, and does it matter
Start with the legal fact, because it determines everything about what is in the capsule. Vinpocetine is an approved medicine in some countries and an unapproved drug in the United States, where it is nonetheless sold as a dietary supplement. When investigators quantified the contents of cognitive-enhancement supplements, vinpocetine was one of five unapproved drugs they found in them Cohen 2021. Nothing on this shelf is a botanical preparation, and no purchaser should reason about it as one.
The consequence: the label number is a claim, not a specification. A prescription tablet of Cavinton is made to a pharmacopoeial assay. A supplement labeled 10 mg is made to a market. The Cohen analysis exists precisely because the quantity in the bottle and the quantity on the bottle are separate questions for this class of product Cohen 2021.
Vinpocetine, vincamine and periwinkle are three different purchases. Vincamine is the natural alkaloid of Vinca minor; vinpocetine is a semisynthetic ester derived from it; a periwinkle herb powder is neither, and none of the trials used one Dong 2024. A product sold as “periwinkle extract” is not a cheaper vinpocetine.
Take it with food, and the reason is exposure rather than tolerance. Oral bioavailability is low and first-pass extraction is extensive, so the fraction that survives is sensitive to how it is taken; the metabolite is what carries the exposure Petric 2023. A person taking it fasted and concluding it does nothing may have measured their stomach.
What would have to be true, and how you would know it was not
1. Blood pressure, because it is the mechanism's own receipt. A PDE1 inhibitor that raises cGMP in vascular smooth muscle is a vasodilator. Predict a small fall in resting systolic blood pressure — a few millimeters of mercury — on a home cuff averaged across seven mornings at 30 mg/day, against a seven-morning baseline taken before starting. If nothing moves at all, the vascular arm of the mechanism is not engaging at your dose, and the cognitive claim that rests on it should be treated as unsupported in you specifically.
2. The cognitive read-out, run properly or not at all. Trail Making A and B and a digit-symbol substitution test, administered at day 0 and again at week 8, same time of day, same caffeine. Predict no change beyond the practice effect in a healthy adult, because no trial has ever found one in that population. What will fool you is the money: this is a member-tier product with a drug-sounding mechanism, and expectation moves a digit-symbol score more reliably than 30 mg of anything.
3. The prediction that cuts against the product, and it is a hard stop rather than a disappointment. Predict that in anyone who could become pregnant, the expected value of this compound is negative regardless of whether the cognitive effect is real, because the developmental toxicology is positive and the efficacy data in healthy people is absent Catlin 2018. There is no dose at which an unmeasurable benefit outweighs a measured fetal effect.
What would settle it: an 8-week randomized crossover in healthy adults with apovincaminic acid measured at steady state alongside the cognitive battery Petric 2023. Nobody has run it.
What nobody has tested yet
There is no exposure-response curve for anything a buyer wants. A population pharmacokinetic model of apovincaminic acid now exists Petric 2023, and not one cognitive endpoint has ever been measured in the same people. Joining those two datasets is one trial with two extra blood draws, and it would tell you whether 10 mg and 30 mg are different drugs or the same one.
Nobody has tested the sodium-channel arm as a hypothesis. If use-dependent sodium block is doing the work in ischemia Dong 2024, then vinpocetine should behave like a weak antiepileptic, and its effects should be largest where firing rates are highest. No trial has compared it against a known sodium channel blocker on any shared endpoint.
The human reproductive question is entirely unstudied and will stay that way. The rat and rabbit datasets are the whole developmental record Catlin 2018, extended only by an embryo-culture experiment Ritchie 2023. No human study will be run, which means the animal result is not an early signal awaiting confirmation — it is the final answer this compound is ever going to get.
And nobody has asked what happens on stopping. A chronic PDE1 inhibitor plausibly shifts cyclic nucleotide set points; whether there is a rebound after months of daily use has never been looked for.
Vinpocetine — its own safety story, not its category's
This is the part most retailers leave out, so here it is with the numbers. Pregnant Sprague-Dawley rats, 25 per group, received vinpocetine orally at 0 to 60 mg/kg on gestation days 6 to 20; New Zealand White rabbits, 8 per group, on gestation days 7 to 28. The result was dose-dependent increases in fetal resorption, reduced fetal weight, and ventricular septal defects in rats at 60 mg/kg Catlin 2018. This is the dataset behind the 2019 FDA warning that vinpocetine may cause a miscarriage or harm fetal development and should not be taken by women of childbearing age.
And there is now a candidate mechanism for it. In rat whole-embryo culture both vinpocetine and its circulating metabolite produced concentration-dependent bradycardia from 100 nM, with arrhythmias at higher concentrations Ritchie 2023. An embryo with a slowed, irregular heart is a plausible route from a maternal dose to a resorption, which upgrades the finding from a regulatory line to a biological one.
The regulatory position is not a technicality. Vinpocetine is a prescription medicine in several countries and is not accepted as a dietary ingredient in the United States, which is exactly why it appears in a published list of unapproved drugs found in cognitive-enhancement supplements Cohen 2021. Buying it in a supplement aisle does not make it a nutrient; it makes it an unmonitored drug.
Bleeding, and the reason it will not show on a drug level. Vinpocetine has antiplatelet activity, so with warfarin, apixaban, rivaroxaban, clopidogrel or daily aspirin the additivity is pharmacodynamic. Nothing changes in the anticoagulant's concentration; what changes is bruising, nosebleeds and, on warfarin, the INR. Blood pressure may also fall, which matters if you are already on an antihypertensive.
Who should not take it: anyone who is pregnant, might become pregnant, or is trying to conceive — and that exclusion is categorical rather than cautionary Catlin 2018; anyone on an anticoagulant or antiplatelet; anyone with low resting blood pressure; and any athlete subject to testing who has not checked their sport's list, since this is a pharmaceutical in most of the world.
Sources read for this page
- Catlin N, et al. Embryo-fetal development studies with the dietary supplement vinpocetine in the rat and rabbit. Birth Defects Research 2018 · PMID 29460393
- Ritchie HE, et al. Effect of vinpocetine on embryonic heart rate in vitro. Current Research in Toxicology 2023 · PMID 37753450
- Shekarian M, et al. Neuroprotective effects of vinpocetine, as a phosphodiesterase 1 inhibitor, on long-term potentiation in a rat model of Alzheimer's disease. BMC Neuroscience 2023 · PMID 36927298
- Petric Z, et al. Clinical Pharmacology of Vinpocetine: Properties Revisited and Introduction of a Population Pharmacokinetic Model for Its Metabolite, Apovincaminic Acid (AVA). Pharmaceutics 2023 · PMID 37896263
- Panda PK, et al. Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Neurocritical Care 2022 · PMID 35488169
- Dong ZC, et al. Synthesis and pharmacological activity of vinpocetine derivatives. RSC Advances 2024 · PMID 38454939
- Cohen PA, et al. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. Neurology Clinical Practice 2021 · PMID 34484905
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Clarity on tasks that fade with age or circulation: reading comprehension held across a full hour, following a long conversation in a noisy room. Its best evidence sits in vascular cognitive problems, so in a healthy user the expected signal is small enough that you need the task to be hard.
- How long before it means anything: Four to eight weeks, taken with food. Cerebral blood flow effects are not acute in any way you would notice, whatever the marketing around this compound implies.
- What will fool you: Two hard limits matter more than your trial does: it carries an FDA warning against use in pregnancy, and it interacts with blood thinners. Beyond that, the evidence base is thinner than ginkgo's for the same population, so a null result here is not surprising and does not need explaining away.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Vinpocetine — safety & side effects
- Headache, dizziness, flushing and GI upset.
- Avoid in pregnancy — the FDA issued a specific warning that vinpocetine may cause miscarriage or harm fetal development. It is banned as a supplement in several countries.
- Additive bleeding risk with anticoagulants and antiplatelets — warfarin, apixaban, rivaroxaban, clopidogrel, and aspirin at any dose. The interaction is pharmacodynamic rather than metabolic, so it does not show up as a changed drug level; it shows up as bruising, nosebleeds or a raised INR. May lower blood pressure.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Vinpocetine in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Vinpocetine
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Vinpocetine — frequently asked questions
What is Vinpocetine?
A compound that increases cerebral blood flow and glucose/oxygen use in the brain — used for memory, focus and cognitive circulation.
What is the suggested dose of Vinpocetine?
10–30 mg daily with food. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Vinpocetine dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Vinpocetine?
Coach Cam sources Vinpocetine from vetted, top-rated brands on iHerb — use the buy link on this page.
Vinpocetine inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Vinpocetine is used for
Vinpocetine appears under 1 goal in the goal router.
Related Cognitive & Mood supplements
Where this goes next
Vinpocetine is the cerebral metabolism arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.